Acceder

Brickell Biotech Announces Publication of its U.S. Phase 2b Study Results for Sofpironium Bromide in Patients with Prima

2 respuestas

Brickell Biotech Announces Publication of its U.S. Phase 2b Study Results for Sofpironium Bromide in Patients with Prima

Suscribirse

Brickell Biotech Announces Publication of its U.S. Phase 2b Study Results for Sofpironium Bromide in Patients with Prima

#1

Brickell Biotech Announces Publication of its U.S. Phase 2b Study Results for Sofpironium Bromide in Patients with Prima

steri

20/02/20 13:44

https://www.globenewswire.com/news-release/2020/02/20/1987666/0/en/Brickell-Biotech-Announces-Publication-of-its-U-S-Phase-2b-Study-Results-for-Sofpironium-Bromide-in-Patients-with-Primary-Axillary-Hyperhidrosis-in-the-Journal-of-the-American-Acad.html

#2

Re: Brickell Biotech Announces Publication of its U.S. Phase 2b Study Results for Sofpironium Bromide in Patients wit...

steri

20/02/20 14:24

Mucha demanda en la preapertura

#3

Re: Brickell Biotech Announces Publication of its U.S. Phase 2b Study Results for Sofpironium Bromide in Patients wit...

steri

20/02/20 15:35

+80%

Te puede interesar...

Más recomendado Más leído

Prensa económica. Los comentarios se los dejo a VDs
Keith Gill (Roaring Kitty) no es uno de los nuestros, es una ballena.
Valoraciones, expectativas de beneficios y “Pain Trade”.
El gráfico semanal: Salesforce y la compleja búsqueda del equilibrio en la valoración de las tecnológicas
Las Bolsas reviven en mayo bajo el liderazgo de las tecnológicas

Guía Básica

Brokers destacados